ArticlePatient preference and adherence2019
Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain.
Article in Patient preference and adherence, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The effects of continuous care model using a smartphone application on adherence to treatment and self-efficacy among patients with multiple sclerosis.BMC medical informatics and decision making · 2022Trial
- Psychological resilience predicts medication adherence in multiple sclerosis.Acta neurologica Belgica · 2026Review
- Association of Physician-Patient Communication and Treatment Satisfaction with Adherence to Disease-Modifying Therapies Among Patients with Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Adherence to therapeutic recommendation in relapsing-remitting multiple sclerosis patients.Frontiers in immunology · 2025Article
- Article
- Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis.Neurology and therapy · 2024Article
- Real-world persistence of multiple sclerosis disease-modifying therapies.European journal of neurology · 2024Article
- Costs of Potential Medication Wastage Due to Switching Treatment Among People With Multiple Sclerosis.Journal of health economics and outcomes research · 2024Article
- Beliefs about Medicines and the Level of Intentional Non-Adherence to Treatment among Patients with Multiple Sclerosis Treated with First-Line Drugs.Journal of clinical medicine · 2023Article
- Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study.Frontiers in neurology · 2023Article
- Factors Associated with Therapeutic Adherence in Multiple Sclerosis in Spain.Patient preference and adherence · 2023Article
- Adherence to Therapy in Patients with Multiple Sclerosis-Review.International journal of environmental research and public health · 2022Review
- Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates.Neurology and therapy · 2021Review
- Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.Journal of managed care & specialty pharmacy · 2021Article
- Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.Journal of managed care & specialty pharmacy · 2021Article
- Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis.Therapeutic advances in neurological disorders · 2021Article
- Medication adherence/persistence among patients with active multiple sclerosis in Finland.Acta neurologica Scandinavica · 2020Article
- Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.Journal of neurology · 2020Article
- BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECTPatient preference and adherence · 2020Article
- Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care.Advances in therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an increasingly significant role in treatment decision-making. This study aims to evaluate the degree of adherence, along with other variables that may influence this adherence, in Spain.
methodsA cross-sectional study was conducted with 157 MS patients with disease-modifying treatments. Adherence was assessed using the Morisky Green scale, and other related factors were measured using a questionnaire that addressed demographics, disease characteristics, global perception of pathology, impact of medication on patient's life, and treatment decision-making.
resultsThe adherence rate was 71% and was associated with the following variables: older age, more treatments received, time to diagnosis 5-10 years, absence of exacerbations, better cognitive status, being married/in a union, clear information about the disease, and higher treatment satisfaction. The main cause for non-compliance was forgetfulness (27%).
conclusionThe adherence rate is acceptable. It is widely known that treatment satisfaction is related to adherence. In our study, patients' level of satisfaction was higher with oral treatments. However, oral administration showed a greater lack of adherence. The main cause of lack of adherence was forgetfulness. In relation to other variables, cognitive status and family support showed a correlation with treatment adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.